<DOC>
	<DOCNO>NCT01843738</DOCNO>
	<brief_summary>Patients ask take part melanoma spread organ body ( metastatic ) . As part study , patient receive radiation therapy approve drug ( Vemurafenib ) .</brief_summary>
	<brief_title>Radiation Use During Vemurafenib Treatment</brief_title>
	<detailed_description>Patients treat vemurafenib plus radiation therapy ( RT ) base upon administration schedule . The start dose vemurafenib patient 's baseline tolerating dose , 720 - 960 mg mouth . Patients must tolerate minimum 720mg one cycle ( 28 day ) prior enrollment .</detailed_description>
	<criteria>Age &gt; 18 year old Diagnosis BRAFV600 mutate Stage IV unresectable Stage III melanoma Actively receive treatment vemurafenib single agent tolerate least 720 mg bid one cycle ( 28 day ) . In opinion investigator , patient progress area radiation may provide benefit either : Symptom control Oligoprogression , define progression 3 area focal treatment would provide benefit . Patients brain metastasis allow provided meet follow criterion : Small , &lt; 1cm metastasis untreated allow long opinion investigator require immediate treatment radiation surgery Asymptomatic , treat brain metastasis stable 4 week prior study entry allow If patient require steroid brain metastasis , must stable dose two week prior study entry , maintain steroid dosing radiation treatment Adequate bone marrow function define : ANC &gt; 1.0 k/uL , Platelets &gt; 75 k/uL , Hemoglobin &gt; 8 g/dL Adequate hepatic function : Total bilirubin &lt; 1.5 time institutional upper limit normal , ALT/AST &lt; 2.5 time institutional upper limit normal Adequate renal function define serum creatinin &lt; 1.5 time upper limit normal . Negative serum pregnancy test screen woman child bear potential within 10 day start vemurafenib treatment . Women nonchildbearing potential may include either surgically sterile postmenopausal &gt; 1 year Fertile men woman must agree use acceptable method birth control treatment least 2 month discontinuation vemurafenib . Able willing provide inform consent approve consent form conform federal institutional guideline . Screening QTc interval &gt; 450 msec EKG Known HIV positivity AIDSrelated illness , active HBV , active HCV . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , serious cardiac arrhythmia require medication , uncontrolled hypertension , cerebrovascular accident transient ischemic attack , symptomatic pulmonary embolism . Malabsorption disorder would preclude adequate vemurafenib absorption . Other medical condition present opinion investigator hinder subject ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>